Orexo Gets U.S. Nod for Addiction Tablet to Rival Suboxone
This article is for subscribers only.
Orexo AB won U.S. regulatory approval for a tablet to treat addiction to heroin and prescription painkillers. The Swedish drugmaker’s stock surged to the highest price in more than five years.
The Food and Drug Administration cleared the drug known as Zubsolv for opioid dependence, the Uppsala, Sweden-based company said in a statement today. Zubsolv combines the medicines buprenorphine and naloxone to ease withdrawal symptoms and block the high of opioids.